EU/3/15/1510

About

On 19 June 2015, orphan designation (EU/3/15/1510) was granted by the European Commission to Mitsubishi Tanabe Pharma Europe Ltd, United Kingdom, for edaravone for the treatment of amyotrophic lateral sclerosis.

The sponsorship was transferred to Mitsubishi Tanabe Pharma GmbH, Germany, in March 2019.

Key facts

Active substance
edaravone
Medicine name
-
Disease / condition
Treatment of amyotrophic lateral sclerosis
Date of first decision
19/06/2015
Outcome
Positive
EU designation number
EU/3/15/1510

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Mitsubishi Tanabe Pharma GmbH
Willstaetterstrasse 30
Heerdt
Duesseldorf
North Rhine-Westphalia
40549
Germany
Tel. +49 211 520 5440
E-mail: Pv-info@mt-pharma-de.com

 

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating